150 related articles for article (PubMed ID: 38831157)
1. Relapse during and after regular single-dose rituximab treatment in adult patients with steroid-dependent nephrotic syndrome.
Saito E; Oura A; Kyo T; Ishigaki S; Kamei H; Nakamura Y; Soma J; Nakaya I
Clin Exp Nephrol; 2024 Jun; ():. PubMed ID: 38831157
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital.
Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
An Pediatr (Engl Ed); 2022 Feb; 96(2):83-90. PubMed ID: 35144901
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
Lan L; Lin Y; Yu B; Wang Y; Pan H; Wang H; Lou X; Lang X; Zhang Q; Jin L; Yang Y; Xiao L; Chen J; Han F
Am J Nephrol; 2024; 55(1):25-36. PubMed ID: 37963441
[TBL] [Abstract][Full Text] [Related]
5. [Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: a tertiary hospital].
Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
An Pediatr (Engl Ed); 2021 Jan; ():. PubMed ID: 33518484
[TBL] [Abstract][Full Text] [Related]
6. Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
Taşdemir M; Canpolat N; Yıldız N; Özçelik G; Benzer M; Saygılı SK; Özkayin EN; Türkkan ÖN; Balat A; Candan C; Çelakıl M; Yavuz S; Akıncı N; Göknar N; Akgün C; Tülpar S; Alpay H; Sever FL; Bilge İ
Turk J Med Sci; 2021 Aug; 51(4):1781-1790. PubMed ID: 33581711
[TBL] [Abstract][Full Text] [Related]
7. Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
Yamamoto R; Imai E; Maruyama S; Yokoyama H; Sugiyama H; Takeda A; Tsukamoto T; Uchida S; Tsuruya K; Shoji T; Hayashi H; Akai Y; Fukunaga M; Konta T; Nishio S; Goto S; Tamai H; Nagai K; Katafuchi R; Masutani K; Wada T; Nishino T; Shirasaki A; Sobajima H; Nitta K; Yamagata K; Kazama JJ; Hiromura K; Yasuda H; Mizutani M; Akahori T; Naruse T; Hiramatsu T; Morozumi K; Mimura T; Saka Y; Ishimura E; Hasegawa H; Ichikawa D; Shigematsu T; Sato H; Narita I; Isaka Y;
J Nephrol; 2022 May; 35(4):1135-1144. PubMed ID: 35366214
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndrome.
Sobue Y; Nishi K; Kamei K; Inoki Y; Osaka K; Kaneda T; Akiyama M; Sato M; Ogura M; Ishikura K; Ishiguro A; Ito S
Pediatr Nephrol; 2024 Jun; 39(6):1825-1835. PubMed ID: 38270600
[TBL] [Abstract][Full Text] [Related]
9. Rituximab experience in children with nephrotic syndrome: what have we observed differently.
Girişgen İ; Yüksel S; Pekal Y
Turk Pediatri Ars; 2020; 55(1):60-66. PubMed ID: 32231451
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
[TBL] [Abstract][Full Text] [Related]
11. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment.
Iwabuchi Y; Takei T; Moriyama T; Itabashi M; Nitta K
Medicine (Baltimore); 2014 Dec; 93(29):e300. PubMed ID: 25546674
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
Ruggenenti P; Ruggiero B; Cravedi P; Vivarelli M; Massella L; Marasà M; Chianca A; Rubis N; Ene-Iordache B; Rudnicki M; Pollastro RM; Capasso G; Pisani A; Pennesi M; Emma F; Remuzzi G;
J Am Soc Nephrol; 2014 Apr; 25(4):850-63. PubMed ID: 24480824
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of children with steroid-dependent nephrotic syndrome with rituximab].
Huang J; Du J; Wang S; Xiao L; Zhao X
Zhonghua Er Ke Za Zhi; 2014 Jul; 52(7):521-4. PubMed ID: 25224058
[TBL] [Abstract][Full Text] [Related]
15. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
Ramachandran R; Bharati J; Rao I; Kashif AW; Nada R; Minz R; Gupta KL; Kohli HS
Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
[TBL] [Abstract][Full Text] [Related]
16. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
19. Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome.
Niu XL; Hao S; Wang P; Zhang W; Guo GM; Wu Y; Kuang XY; Zhu GH; Huang WY
Biomed Rep; 2016 Aug; 5(2):237-242. PubMed ID: 27446549
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
